Fair Value Calculator Fair Value Calculator
EN DE

2389 (2389) Fair Value & Analysis

Healthcare · Market cap HK$460M

2 2389 2389 · HK
PriceHK$0.0760
Fair ValueHK$0.0920
Upside+21.0%
Quality50/100
Watch 2389 for free — get notified when fair value or trend changes. Watch for free
Evidence: Low Range HK$0.0593 – HK$0.1199

Fair value as of: Jul 2, 2026

From 3 valuation models · updated today

Share price +13.4% over the past month.

Price vs Fair Value (12 months)

HK$0.0950 HK$0.0600 Fair Value HK$0.0920 Jun 2025 Jul 2026

12‑month range HK$0.0600 – HK$0.0950 · fair‑value band HK$0.0593 – HK$0.1199 · the HK$0.0760 price screens below the HK$0.0920 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

2389 (2389) currently trades at HK$0.0760, while our model-based Fair Value estimate is HK$0.0920 — implying the stock looks roughly 21.0% undervalued today. We read business quality at 50/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

Over the trailing twelve months, 2389 generated revenue of HK$157M at a net margin of -64.2%. Revenue grew 5.2% year over year. It earns a return on equity of -5.8%. The balance sheet holds a net cash position of HK$26.4M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$157M
Revenue growth (YoY) +5.2%
Net margin -64.2%
Return on equity -5.8%
Free cash flow −HK$18.0M FY2025
Operating margin -29.7%
More key figures
Net cash HK$26.4M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

2389 reported revenue of HK$157M in FY2025 versus HK$204M in FY2021, a compound −6.3%/yr. Reported net income was −HK$101M in FY2025.

Revenue −6.3%/yr
FY21 HK$204M
FY22 HK$166M
FY23 HK$140M
FY24 HK$150M
FY25 HK$157M
Net income
FY21 −HK$39.4M
FY22 −HK$97.7M
FY23 −HK$61.9M
FY24 −HK$116M
FY25 −HK$101M

Is 2389 fairly valued? → Check now

Similar stocks

6 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock Price Fair Value vs Fair Value
HCA Healthcare, Inc H1CA34 R$95.75 R$123.65 +29%
Fresenius SE FSNUY $11.47 $8.55 -25%
5225 5225 8.71 MYR 4.87 MYR -44%
IHHHF IHHHF $1.71 $1.17 -32%
Tenet Healthcare Corporation THC $164.77 $280.85 +70%
Rede D'Or São Luiz S.A RDOR3 R$32.50 R$46.04 +42%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap Stocks

Frequently asked questions

Is 2389 (2389) undervalued?
As of Jul 2, 2026, our model estimates a fair value of HK$0.0920 versus a price of HK$0.0760 — about +21% (undervalued). Model-based estimate, not financial advice.
What is the fair value of 2389?
Our model-based fair value for 2389 is HK$0.0920 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$0.0760.
What is the quality score of 2389?
2389 has a Quality Score of 50/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.
What is the revenue of 2389 (2389)?
2389 reported trailing-twelve-month revenue of about HK$157M (latest available figure, as of Jul 2, 2026).
What is the net profit margin of 2389?
The net profit margin of 2389 is about -64.2%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.